Innoviva(INVA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million Innoviva Specialty Therapeutics' (IST) marketed portfolio grew 38% year-over-year, achieving net product sales of $21.7 million Important treatment guidelines and guidance updates recognized our key products: XACDURO by 2024 Infectious Diseases Society of America (IDSA); XERAVA by 2024 Surgical Infection Society X ...